NCIt definition : A humanized immunoglobulin G1 (IgG1)-variant monoclonal antibody directed against
the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation
274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities.
Upon administration, garivulimab specifically targets and binds to PD-L1, blocking
its binding to and activation of its receptor, programmed cell death 1 (PD-1; PDCD1;
CD279; programmed death-1). This reverses T-cell inactivation caused by PD-L1/PD-1
signaling, increases T-cell expansion and enhances the cytotoxic T-lymphocyte (CTL)-mediated
anti-tumor immune response against PD-L1-expressing tumor cells. In addition, BGB-A333
blocks the interaction between PD-L1 and its other receptor, the immunostimulatory
molecule cluster of differentiation 80 (CD80; B7-1). This prevents PD-L1/CD80 signaling
and inhibits the induction of PD-L1-induced apoptosis of activated CD8 T-cells and
increases T-cell proliferation. PD-L1 is overexpressed by many human cancer cell types.
PD-L1 binding to PD-1 on activated T-cells suppresses the immune system and results
in immune evasion. PD-1 negatively regulates T-cell activation.;
UNII : CSJ7UEQ4D9;
CAS number : 2342597-81-1; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2342597-81-1
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Semantic type(s)